China's top envoy to Moscow shot down talk of a potential US-Russia alliance against Beijing under the Trump administration as reflecting a "cold war mindset" while painting a rosy picture of the Sino ...
"China is very careful. They're very cautious," Oleksandr Merezhko, head of Ukraine's Foreign Affairs Committee, told ...
TAIPEI, Taiwan (AP) — Along with fulminating against the United States, China’s Foreign Minister Wang Yi reasserted China’s South China Sea claims, blasted Japan for its past aggression and covered a ...
BEIJING (AP) — Chinese Foreign Minister Wang Yi said China will continue to retaliate for the United States’ “arbitrary ...
Trump’s overtures to Moscow were met by increasing attacks in Ukraine, leading to sanctions threats from the president.
The New Indian Express on MSN4d
China's foreign minister condemns US tariffs, accuses Washington of 'meeting good with evil'BEIJING: Chinese Foreign Minister Wang Yi said China will continue to retaliate to the United States' "arbitrary tariffs" and accused Washington of "meeting goo ...
3d
GlobalData on MSNHutchmed concludes enrolment in Phase II trial of fanregratinib for IHCCHutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...
Amid a near-complete reversal in U.S. foreign policy, more nations may look to China to fill the role that the United States ...
She joined Newsweek in January 2023, having previously worked as a reporter at the Daily Express, and is a graduate ... via email at [email protected]. China is "too smart" to commit any of ...
Chinese Foreign Minister Wang Yi, also a member of the Political Bureau of the Communist Party of China Central Committee, ...
During his first term, Trump imposed tariffs with a flourish—targeting imported solar panels, steel, aluminum and pretty much everything from China ... post-World War II role of promoting ...
20d
Clinical Trials Arena on MSNInnoCare Pharma receives approval for CLL/SLL combination therapy trial in ChinaChina's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) with orelabrutinib as a first-line therapy for chronic lymphocytic leukaemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results